References
- Kempe A, Hall CB, MacDonald NE, Foye HD, Woodin KA, Cohen HJ, et al. Influenza in children with cancer. J Pediatr 1989; 115: 33–9.
- Hayden FG. Prevention and treatment of influenza in immunocompromised patients. Am J Med 1997; 102: 55–60.
- Englund JA, Champlin RE, Wyde PR, Kantarjian H, Atmar RL, Tarrand J, et al. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis 1998; 26: 1418–24.
- Hayden FG, Osterhaus ADME, Treanor JJ, Fleming DM, Aoki FY, Nicholson KG, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infection. N Engl J Med 1997; 337: 874–80.
- Penn C, Osterhaus A. Zanamivir: a rational approach to influenza B. Scand J Infect Dis 2001; 33: 33–40.
- Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D, et al. Use of selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999; 341: 1336–43.
- Lalezari J, Campion K, Keene O, Silagy C. Zanamivir for treatment of influenza A and B infection in high-risk patients. Arch Intern Med 2001; 161: 212–7.
- Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC. Webster RG. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 1998; 178: 1257–12562.
- Shinjo M. Influenza in children. Popular Med 2000; 210: 46–9.
- Whimbey E, Englund JA, Couch RB. Community respiratory virus infection in immunocompromised patients with cancer. Am J Med 1997; 102: 10–8.